ZIF-8 / ZnO composite nano-material, preparation method thereof and application of ZIF-8 / ZnO composite nano-material in bacteriostasis

By generating ZnO in situ on ZIF-8 and forming ZIF-8/ZnO composite nanomaterials, the problem of insufficient antibacterial performance of ZIF-8 is solved, and the antibacterial effect on drug-resistant strains is significantly improved, and the low concentration is achieved Effectively inhibit bacterial growth.

CN118987026APending Publication Date: 2024-11-22LIAONING UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411087549.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The minimum bactericidal concentration of existing ZIF-8 as an antibacterial material for ampicillin-resistant E. coli MBC value is as high as 250mg/mL, and its antibacterial performance is insufficient and it is difficult to effectively inhibit bacterial infection.

Method used

Under the action of the catalyst AgNO3, the ZIF-8 structure is converted into ZnO in situ to prepare ZIF-8/ZnO composite nanomaterial to improve its antibacterial effect.

Benefits of technology

The MIC and MBC values ​​of ZIF-8/ZnO composite nanomaterials for E. coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus are in the range of 4-16μg/mL, which significantly improves the antibacterial properties and can be very good at The ideal antibacterial effect is achieved at low amounts without causing bacterial resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987026A_ABST
    Figure CN118987026A_ABST
Patent Text Reader

Abstract

The invention discloses a ZIF-8 / ZnO composite nanomaterial, a preparation method thereof and an application of the ZIF-8 / ZnO composite nanomaterial in bacteriostasis. The ZIF-8 / ZnO composite nano material is prepared by generating ZnO on the surface of ZIF-8 in situ under the catalysis of a catalyst AgNO3 on the basis of ZIF-8. The inhibition rate of the ZIF-8 / ZnO composite nanomaterial prepared by the invention on 10 < 6 > CFU / mL of escherichia coli, staphylococcus aureus and methicillin-resistant staphylococcus aureus can reach 99.99% or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical materials, and specifically relates to a preparation method and application of a ZIF-8-based nano antibacterial material. Background Art

[0002] Bacterial infections pose a major threat to global public health security and can cause a variety of diseases ranging from simple skin infections to life-threatening sepsis or septicemia. For decades, antibiotics have been the main method for clinical treatment of bacterial infections. The abuse of antibiotics has led to the emergence of bacterial resistance and the evolution of many resistant strains. It is reported that at least 700,000 people die from drug-resistant bacterial infections each year worldwide. Therefore, in this context, it is particularly important to find an antibacterial drug that can replace antibiotics.

[0003] ZIF-8 not only has a highly porous structure, but also can serve as a reservoir for metal ions (zinc ions). Zinc ions are an effective antibacterial agent that can induce cell deformation, cell wall rupture, and cytoplasmic leakage, all of which can lead to bacterial growth inhibition or death. This means that ZIF-8 has the potential to replace antibiotics as an antibacterial drug. However, existing studies have shown that the minimum bactericidal concentration (MBC) value of ZIF-8 as an antibacterial therapeutic material for ampicillin-resistant Escherichia coli is as high as 250 mg / mL, and the antibacterial performance needs to be improved. Summary of the invention

[0004] In order to solve the problem that the antibacterial performance of ZIF-8 itself is insufficient, the present invention provides a microcatalytic method, by adding a catalyst AgNO3 to in-situ convert the ZIF-8 structure into ZnO to prepare a ZIF-8 / ZnO composite nanomaterial, thereby improving the antibacterial effect of ZIF-8.

[0005] The technical solution adopted by the present invention is: a ZIF-8 / ZnO composite nanomaterial, wherein the ZIF-8 / ZnO composite nanomaterial is prepared by in-situ generating ZnO on the surface of ZIF-8 under the catalysis of catalyst AgNO3 on the basis of ZIF-8.

[0006] A preparation method of a ZIF-8 / ZnO composite nanomaterial comprises the following steps: dissolving a catalyst AgNO3 in a methanol aqueous solution to form an AgNO3 solution; adding ZIF-8 to the AgNO3 solution and stirring at room temperature for 1-2 hours, centrifuging the obtained mixture, washing with ethanol, and drying to obtain the ZIF-8 / ZnO composite nanomaterial.

[0007] Furthermore, in terms of mass ratio, AgNO3:ZIF-8=0.65-0.70:1.

[0008] Furthermore, the preparation method of ZIF-8 includes the following steps: dissolving Zn(NO3)2·6H2O in methanol and stirring at room temperature for 10-20 minutes; then, slowly adding a methanol solution containing dimethylimidazole and continuing to stir at room temperature for 22-26 hours; then, centrifuging and drying the resulting mixture to obtain ZIF-8.

[0009] Further, 2.5-3.5 g Zn(NO3)2·6H2O was added per 100 mL methanol.

[0010] Furthermore, the molar ratio of Zn(NO3)2·6H2O to dimethylimidazole is 1:3.5-4.5.

[0011] Furthermore, the dropping speed of the methanol solution containing dimethylimidazole is 8-12 mL / min.

[0012] The invention provides an application of a ZIF-8 / ZnO composite nano material in antibacterial.

[0013] Furthermore, the bacteria include Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus.

[0014] Furthermore, the dosage of ZIF-8 / ZnO composite nanomaterial is 4-16 μg / mL.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] 1. The ZIF-8 / ZnO composite nanomaterial provided by the present invention has a simple preparation method, its raw materials are economical and easily available, and the obtained material has high stability.

[0017] 2. The MIC value and MBC value of the ZIF-8 / ZnO composite nanomaterial provided by the present invention against Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus are all within the range of 4-16 μg / mL. This shows that the composite material provided by the present invention can achieve an ideal antibacterial effect as an antibacterial drug with only a very small amount, and has good antibacterial activity against the three pathogens.

[0018] 3. The ZIF-8 / ZnO composite nanomaterial provided by the present invention achieves the purpose of antibacterial by releasing inorganic metal ions (zinc ions, silver ions). The antibacterial mechanism is physical damage and will not cause bacterial resistance. It also has a good in vitro therapeutic effect on existing drug-resistant bacteria (methicillin-resistant Staphylococcus aureus). BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Scanning electron microscope spectra of ZIF-8 (a) and ZIF-8 / ZnO (b).

[0020] Figure 2 This is the X-ray powder diffraction (XRD) spectrum of ZIF-8 / ZnO.

[0021] Figure 3 This is a graph showing the in vitro antibacterial effects of ZIF-8, ZnO and ZIF-8 / ZnO on Escherichia coli.

[0022] Figure 4 This is the in vitro antibacterial effect diagram of ZIF-8, ZnO and ZIF-8 / ZnO on Staphylococcus aureus.

[0023] Figure 5 This is the in vitro antibacterial effect diagram of ZIF-8, ZnO and ZIF-8 / ZnO on methicillin-resistant Staphylococcus aureus.

[0024] Figure 6 This is the result of measuring the MIC value of ZIF-8 / ZnO against Escherichia coli;

[0025] Among them, groups 1 to 4 corresponded to 8, 4, 2 and 1 μg / mL ZIF-8 / ZnO groups, respectively, group 5 was the blank group, and group 6 was the control group.

[0026] Figure 7 This is the result of measuring the MBC value of ZIF-8 / ZnO against Escherichia coli;

[0027] Among them, a corresponds to the 8 μg / mL ZIF-8 / ZnO group, and b corresponds to the 4 μg / mL ZIF-8 / ZnO group.

[0028] Figure 8 The figure shows the results of the determination of the MIC value of ZIF-8 / ZnO against Staphylococcus aureus;

[0029] Among them, groups 1 to 5 corresponded to 16, 8, 4, 2 and 1 μg / mL ZIF-8 / ZnO groups, respectively, group 6 was the blank group, and group 7 was the control group.

[0030] Fig. 9 This is the result of measuring the MBC value of ZIF-8 / ZnO against Staphylococcus aureus;

[0031] Among them, a corresponds to the 16 μg / mL ZIF-8 / ZnO group, and b corresponds to the 8 μg / mL ZIF-8 / ZnO group.

[0032] Fig.10 The figure shows the results of the determination of the MIC value of ZIF-8 / ZnO against methicillin-resistant Staphylococcus aureus;

[0033] Among them, groups 1 to 5 corresponded to 16, 8, 4, 2 and 1 μg / mL ZIF-8 / ZnO groups, respectively, group 6 was the blank group, and group 7 was the control group.

[0034] Fig.11 This is the result of measuring the MBC value of ZIF-8 / ZnO against methicillin-resistant Staphylococcus aureus; corresponding to the 16 μg / mL ZIF-8 / ZnO group. DETAILED DESCRIPTION

[0035] The present invention will be further described below in conjunction with specific embodiments.

[0036] Example 1

[0037] (I) Preparation method of ZIF-8 / ZnO composite nanomaterials

[0038] 1. Preparation of ZIF-8

[0039] Zn(NO3)2·6H2O (2.98 g, 10 mmol) was dissolved in 100 mL of methanol and stirred at room temperature for 10 min. Then, 100 mL of a methanol solution containing dimethylimidazole (3.28 g, 40 mmol) was slowly added dropwise (drop speed: 12 mL / min) and stirred at room temperature for 24 h. Then, the resulting solid-liquid mixture was centrifuged (5000 rpm, 3 min) and dried at 70 ° C for 24 h to obtain ZIF-8.

[0040] 2. Preparation of ZIF-8 / ZnO composite nanomaterials

[0041] 0.68 g of AgNO3 catalyst was dissolved in 40 mL of methanol containing 4 mL of distilled water to form an AgNO3 solution. Then, 1 g of ZIF-8 was added to the AgNO3 solution and stirred at room temperature for 1 h. Subsequently, the resulting mixture was centrifuged (5000 rpm, 3 min), washed 3 times with ethanol, and dried at 50 ° C for 24 h to obtain ZIF-8 / ZnO composite nanomaterials.

[0042] (II) Results

[0043] 1. Scanning electron microscope

[0044] The ZIF-8 and ZIF-8 / ZnO were observed by scanning electron microscopy. Figure 1 .Depend on Figure 1 The SEM image of ZIF-8 shown in (a) shows that the ZIF-8 particles are in the form of dodecahedral aggregates. Figure 1 The SEM image of ZIF-8 / ZnO shown in (b) shows that when ZIF-8 is treated with 100 mM AgNO3 solution, the edge portion corresponding to the surface of ZIF-8 becomes spherical, indicating that ZnO is in situ generated on the surface of ZIF-8.

[0045] 2. XRD

[0046] The ZIF-8 / ZnO was subjected to X-ray diffraction analysis, and the test results were as follows Figure 2 .Depend on Figure 2 It can be seen that all peaks are sharp and obvious. Compared with existing studies, it can be known that ZIF-8 / ZnO composite nanomaterials contain ZIF-8, ZnO and HAg(IM)2 complexes. HAg(IM)2 represents any silver substance coordinated in a linear manner by IM, including polymer complexes.

[0047] Example 2 Application of ZIF-8 / ZnO composite nanomaterials in antibacterial treatment (I) In vitro antibacterial test of ZIF-8 / ZnO composite nanomaterials

[0048] Here’s how:

[0049] The bacterial colony counting method was used to detect the antibacterial effect of ZIF-8 / ZnO composite nanomaterials on Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. First, the three bacteria were inoculated in LB broth medium and cultured overnight at 37°C with shaking. The overnight cultured bacterial solution was diluted to 10 7 CFU / mL. Then incubate for 4 hours according to the schemes in Tables 1-3. Dilute and plate after 4 hours. The plate results are shown in Figure 3-Figure 5 .

[0050] Table 1 Incubation scheme of different groups with Escherichia coli

[0051]

[0052] Table 2 Incubation schemes of different groups with Staphylococcus aureus

[0053]

[0054] Table 3 Incubation schemes of different groups with methicillin-resistant Staphylococcus aureus

[0055]

[0056] Depend on Figure 3-Figure 5 It can be seen that ZIF-8 / ZnO composite nanomaterials have a significant effect on 6 The inhibition rate of CFU / mL of Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus can reach more than 99.99%.

[0057] (II) Determination of MIC and MBC values ​​of ZIF8 / ZnO composite nanomaterials against three bacteria

[0058] The MIC values ​​of ZIF-8 / ZnO composite nanomaterials against Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus were determined by the microbroth two-fold dilution method. First, the three bacteria were inoculated in LB broth medium and cultured overnight at 37°C with shaking. The overnight cultured bacterial solution was diluted to 10 6 CFU / mL. Then, 100 μL of the above bacterial solution and 100 μL of ZIF-8 / ZnO composite nanomaterial solution of different concentrations were added to the wells of the material group; 100 μL of LB broth was added to the wells of the blank group; 100 μL of the above bacterial solution and 100 μL of water were added to the wells of the control group. Three parallel wells were set for each group.

[0059] After the liquid is added, the 96-well plate is placed in an incubator at 37°C for 24 hours. If the liquid in the well is clear, it means that the bacterial growth is completely inhibited, and if it is turbid, it means the opposite. The minimum concentration that can inhibit bacterial growth is the MIC value. The liquid in the well with a concentration above the MIC value is used to coat the plate. The value with almost no colony growth is the minimum bactericidal concentration MBC value. The MIC value and MBC value determination results of ZIF-8 / ZnO composite nanomaterials for the above three bacteria are shown in the figure. Figure 6-Figure 11 The data results of MIC and MBC values ​​are summarized in Table 4.

[0060] Table 4 Summary of MIC and MBC values ​​of ZIF-8 / ZnO against three bacteria

[0061] MIC value (μg / mL) MBC value (μg / mL) Escherichia coli 4 8 Staphylococcus aureus 8 16 Methicillin-resistant Staphylococcus aureus 16 16

[0062] From Table 4 and Figure 6-Figure 11 It can be seen that the MIC and MBC values ​​of ZIF-8 / ZnO composite nanomaterials against Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus are between 4-16 μg / mL. This shows that the composite material provided by the present invention can achieve an ideal antibacterial effect as an antibacterial drug with only a very small amount, and has good antibacterial activity against the three bacteria.

Claims

1. A ZIF-8 / ZnO composite nanomaterial, characterized in that: The ZIF-8 / ZnO composite nanomaterial is prepared by in-situ generating ZnO on the surface of ZIF-8 under the catalysis of AgNO3, based on ZIF-8.

2. The method for preparing a ZIF-8 / ZnO composite nanomaterial according to claim 1, characterized in that: The preparation method comprises the following steps: dissolving the catalyst AgNO3 in a methanol aqueous solution to form an AgNO3 solution; adding ZIF-8 to the AgNO3 solution and stirring at room temperature for 1-2 hours, centrifuging the obtained mixture, washing with ethanol, and drying to obtain a ZIF-8 / ZnO composite nanomaterial.

3. The preparation method according to claim 2, characterized in that: In terms of mass ratio, AgNO3:ZIF-8=0.65-0.70:

1.

4. The preparation method according to claim 2 or 3, characterized in that: The preparation method of ZIF-8 comprises the following steps: dissolving Zn(NO3)2·6H2O in methanol and stirring at room temperature for 10-20 minutes; then, slowly dropping a methanol solution containing dimethylimidazole and continuing to stir at room temperature for 22-26 hours; then, centrifuging and drying the obtained mixture to obtain ZIF-8.

5. The preparation method according to claim 4, characterized in that: Add 2.5-3.5 g Zn(NO3)2·6H2O per 100 mL methanol.

6. The preparation method according to claim 4, characterized in that: The molar ratio of Zn(NO3)2·6H2O to dimethylimidazole is 1:3.5-4.

5.

7. The preparation method according to claim 4, characterized in that: The dropping speed of the methanol solution containing dimethylimidazole is 8-12 mL / min.

8. Use of the ZIF-8 / ZnO composite nanomaterial according to claim 1 in antibacterial activities.

9. The use according to claim 8, characterized in that: The bacteria include Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus.

10. The use according to claim 9, characterized in that: The dosage of ZIF-8 / ZnO composite nanomaterial is 4-16 μg / mL.

Citation Information

Patent Citations

  • Method for synthesizing ZnO / ZIF-CN / Ag nano-composite material based on ZIF-8

    CN109647529A

  • Method for preparing silver-doped ZnO@ZIF-8 nanoflower compound

    CN109954481A

  • Preparation method of zinc oxide-metal organic framework composite antibacterial material

    CN111034720A

  • Preparation method of inorganic nano material for efficient and lasting disinfection and sterilization

    CN114766512A

  • ZnO-coated HPDA antibacterial nano composite particle as well as preparation method and application thereof

    CN117229631A